9 analysts' median target is $256[FMP target], stock is $197, +29.7% upside potential. After Q2 +13.6% EPS beat[FMP earnings], the stock moved +1.2%.
C+ = MoonshotScore 37[9-pillar formula] + Council 3/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q1 consensus: revenue $65.2B[FMP est], EPS $2.38[FMP est]. 8 consecutive quarters of beat[FMP earnings].
Q2 EPS +13.6% beat[FMP] but the stock +1.2% D+1[FMP D+1]. Aaron Alt promised $146.0M CapEx + a sequential decline in Q1 during the Q2 earnings call[Aaron Alt capex transcript].
Watchlist
Fy26 Eps Guidance Increase
fy26_eps_guidance_increase
Cardinal Health is raising its fiscal year 2026 earnings per share guidance to a range of $10.15 to $10.35, representing year-over-year EPS growth of 23% to 26%.
"Our new range is $10.15 to $10.35, up from the at least $10 interim guidance update. This updated outlook represents year-over-year EPS growth of 23% to 26%."
- Aaron Alt, CFO - Q2 FY26 Earnings Call - February 5, 2026
Pharmaceutical Segment Profit Growth
pharmaceutical_segment_profit_growth
Cardinal Health is raising its pharma segment profit outlook to a range of 20% to 22% growth, up from the prior range of 16% to 19%.
"For pharma segment profit, we are pleased to raise our outlook to a range of 20% to 22% growth, up from the prior range of 16% to 19%."
- Aaron Alt, CFO - Q2 FY26 Earnings Call - February 5, 2026
Other Growth Businesses Profit Growth
other_growth_businesses_profit_growth
Cardinal Health is increasing its segment profit guidance for other to a range of 33% to 35% growth, up from the prior range of 29% to 31%.
"We are increasing our segment profit guidance for other to a range of 33% to 35% growth, up from the prior range of 29% to 31%."
- Aaron Alt, CFO - Q2 FY26 Earnings Call - February 5, 2026
Specialty Revenue Growth
specialty_revenue_growth
Cardinal Health anticipates its specialty revenues will surpass $50 billion in fiscal 2026.
"As we shared at a recent industry conference, we expect our specialty revenues will surpass $50 billion in fiscal 2026, a testament to our progress in this high-growth, higher-margin space."
- Jason Hollar, CEO - Q2 FY26 Earnings Call - February 5, 2026
Gnpd Profit Guidance Increase
gnpd_profit_guidance_increase
Cardinal Health is raising its guidance to approximately $150 million on GNPD segment profit.
"On GNPD segment profit, we are raising our guidance to approximately $150 million."
- Aaron Alt, CFO - Q2 FY26 Earnings Call - February 5, 2026
Capital Allocation Flexibility
capital_allocation_flexibility
Cardinal Health, by protecting its balance sheet and getting back within its targeted leverage range, has the flexibility to assess how it will allocate capital to create shareholder value.
"And we've, two quarters in, fulfilled our baseline share repurchase commitment of $750 million. And what that means for a business that is continuing to generate strong cash is that we have flexibility to assess how we will create the most shareholder value as we carry forward."
- Aaron Alt, CFO - Q2 FY26 Earnings Call - February 5, 2026
Stock Expert AI - Methodology
9-pillar methodology. Cash Runway and News Sentiment strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 3 bullish (Ray Dalio, Klarman, Munger), 1 bearish (Ken Griffin), 2 neutral (Jim Simons, Buffett).
How is it calculated? ->Quality business, discounted price.
How is it calculated? ->Past Performance
Q2 (February 5, 2026): EPS $3.17 vs $2.79 est[FMP], +13.6% beat. D+1 movement: +1.2%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q2: EPS $3.17 vs $2.79 beat[FMP], stock +1.2% D+1[FMP].
No RPO/backlog concentration disclosed in Q2 earnings call.
Q2 CapEx $146.0M[FMP cashflow]. Q2 op margin 0.8%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Tuesday evening. The framework is ready on this page: Q1 EPS threshold $2.38[FMP], CapEx threshold "below $146.0M"[Aaron Alt]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This CAH (CAH) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.